Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy

Steel, David HW; Smith, Jonathan

doi:10.1002/14651858.cd008214

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New blood vessels, accompanied by fibrotic tissue, grow along the inner surface of the retina and even extend into the vitreous. These fibrotic vessels may contract and cause tractional retinal detachment, eventually resulting in permanent vision loss [24].…”

Section: Development and Pathological Changes Of Drmentioning

confidence: 99%

Emerging role of extracellular vesicles in diabetic retinopathy

Zhu,

Huang,

Sun

et al. 2024

Theranostics

View full text Add to dashboard Cite

Diabetic retinopathy (DR), a complex complication of diabetes mellitus (DM), is a leading cause of adult blindness. Hyperglycemia triggers DR, resulting in microvascular damage, glial apoptosis, and neuronal degeneration. Inflammation and oxidative stress play crucial roles during this process. Current clinical treatments for DR primarily target the advanced retinal disorder but offer limited benefits with inevitable side effects. Extracellular vesicles (EVs) exhibit unique morphological features, contents, and biological properties and can be found in cell culture supernatants, various body fluids, and tissues. In DR, EVs with specific cargo composition would induce the reaction of receptor cell once internalized, mediating cellular communication and disease progression. Increasing evidence indicates that monitoring changes in EV quantity and content in DR can aid in disease diagnosis and prognosis. Furthermore, extensive research is investigating the potential of these nanoparticles as effective therapeutic agents in preclinical models of DR. This review explores the current understanding of the pathological effects of EVs in DR development, discusses their potential as biomarkers and therapeutic strategies, and paves the way for further research and therapeutic advancements.

show abstract

Section: Development and Pathological Changes Of Drmentioning

confidence: 99%

Emerging role of extracellular vesicles in diabetic retinopathy

Zhu,

Huang,

Sun

et al. 2024

Theranostics

View full text Add to dashboard Cite

show abstract

“…Ancak geç dönemde kanama ve yan etki riski kesin olarak bilinmemektedir. [51] Gecikmiş kanamalar (3 ay ve daha uzun sürede) residüel fibrovasküler membranlar, sklerotomi yerlerinden kanama ya da yeni damar gelişmesi şeklinde olabilmektedir. [48,52] Geçmiş dönemlerde sklerotomi bölgelerine kriyoterapi uygu- Persistan ya da rekürren hemorajiler afak gözlerde daha hızlı çekilebilmekte fakik gözlerde ise ortama 9 haftalık bir sürede çekilmektedir.…”

Section: A-vitreus Boşluğuna Kanamaunclassified

Diabetic Intravitreal Hemorrhage

2023

Güncel Retina (Current Retina)

View full text Add to dashboard Cite

Vitreous hemorrhage secondary to proliferative diabetic retinopathy is one of the important causes of severe vision loss in diabetic patients. Although laser photocoagulation therapy is still the gold standard treatment for proliferative diabetic retinopathy, anti-VEGF injections can also be used as adjunctive therapy in preparation for surgery. For vitreous hemorrhages and fibrous tissue proliferation that do not resolve spontaneously, pars plana vitrectomy and endolaser treatment are required. With the developing surgical technique and fast recovery time, it is possible to recommend surgical intervention without waiting for a long time.

show abstract